the necessary hardware and software for patients to self-mange GDM. In the future, Werbie will also create customized kits for type 2 and type 1 non-pregnant women. Our aim is to help all women self-manage diabetes with a focus on psychosocial support, nutrition guidance, and assistance with medication and insulin dosing.

Werbie's GlucoseMama software system is currently undergoing clinical trials with the University of Maryland Medical Center’s Maternal Fetal Medicine Department. It is being used in a four-arm randomized control of 120 patients with GDM. The aim of the study is to keep patients engaged in the self-management of glucose and carbohydrate logging between prenatal appointments to reduce the need for medications and to ensure the best possible outcomes for mothers and neonates. Our preliminary results show an increased rate of compliance with inter-session blood glucose monitoring in the study population who utilized GlucoseMama. In addition, there is a 100% compliance rate in individuals who utilize the system in postpartum screening for type 2 diabetes and postpartum follow-up. The research team is still collecting outcomes on the rates of gestational weight gain and medication use in the study population.